S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results

Merck & Co., Inc. - MRK Stock Forecast, Price & News

$108.84
+0.39 (+0.36%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$107.55
$109.06
50-Day Range
$84.53
$108.45
52-Week Range
$71.50
$109.06
Volume
9.35 million shs
Average Volume
8.57 million shs
Market Capitalization
$275.95 billion
P/E Ratio
18.11
Dividend Yield
2.55%
Price Target
$106.00

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
2.6% Downside
$106.00 Price Target
Short Interest
Healthy
0.77% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.47mentions of Merck & Co., Inc. in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$108.58 M Sold Last Quarter
Proj. Earnings Growth
-0.54%
From $7.38 to $7.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

100th out of 1,038 stocks

Pharmaceutical Preparations Industry

38th out of 510 stocks

MRK stock logo

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Stock News Headlines

Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market? (MRK)
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Why Investors Are Suddenly Excited About Vaxcyte (MRK)
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! pixel
The New Generation Making an Impact on HIV
At All-Time Highs, Merck's Stock Is Nearing a Cliff
Merck Announces First-Quarter 2023 Dividend
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! pixel
Rallying Merck Stock Flashing Historically Bullish Signal
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
Merck to buy Silicon Valley biotech company for $1.35B
Merck to Acquire Imago BioSciences, Inc.
Merck to acquire Imago BioSciences for $1.35 billion
What 13 Analyst Ratings Have To Say About Merck & Co
4 Reasons to Buy This Hybrid of a Growth and Income Stock
See More Headlines
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Company Calendar

Ex-Dividend for 10/7 Dividend
9/14/2022
Dividend Payable
10/07/2022
Last Earnings
10/27/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
68,000
Year Founded
1891

Price Target and Rating

Average Stock Price Forecast
$106.00
High Stock Price Forecast
$122.00
Low Stock Price Forecast
$93.00
Forecasted Upside/Downside
-2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
17 Analysts

Profitability

Net Income
$13.05 billion
Pretax Margin
28.56%

Debt

Sales & Book Value

Annual Sales
$48.70 billion
Cash Flow
$7.34 per share
Book Value
$17.56 per share

Miscellaneous

Outstanding Shares
2,535,400,000
Free Float
2,528,043,000
Market Cap
$275.95 billion
Optionable
Optionable
Beta
0.38

Social Links


Key Executives

  • Mr. Kenneth C. FrazierMr. Kenneth C. Frazier (Age 67)
    Exec. Chairman
    Comp: $4.58M
  • Mr. Robert M. Davis J.D.Mr. Robert M. Davis J.D. (Age 55)
    Pres, CEO & Director
    Comp: $4.4M
  • Ms. Caroline LitchfieldMs. Caroline Litchfield (Age 53)
    Exec. VP & CFO
    Comp: $2.05M
  • Mr. Richard R. DeLuca Jr.Mr. Richard R. DeLuca Jr. (Age 59)
    Exec. VP & Pres of Merck Animal Health
    Comp: $2.05M
  • Dr. Dean Y. Li M.D. (Age 60)
    Ph.D., Exec. VP & Pres of Merck Research Laboratories
    Comp: $2.4M
  • Mr. David Michael Williams (Age 53)
    Exec. VP and Chief Information & Digital Officer
  • Mr. Peter Dannenbaum
    VP of Investor Relations
  • Ms. Jennifer L. Zachary (Age 44)
    Exec. VP & Gen. Counsel
  • Lisa LeCointe-Cephas (Age 40)
    Sr. VP and Chief Ethics & Compliance Officer
  • Ms. Jennifer Mauer
    VP of Global Communications













MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRK shares.
View MRK analyst ratings
or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2023?

17 equities research analysts have issued 1 year target prices for Merck & Co., Inc.'s stock. Their MRK share price forecasts range from $93.00 to $122.00. On average, they expect the company's stock price to reach $106.00 in the next twelve months. This suggests that the stock has a possible downside of 2.6%.
View analysts price targets for MRK
or view top-rated stocks among Wall Street analysts.

How have MRK shares performed in 2022?

Merck & Co., Inc.'s stock was trading at $76.64 at the beginning of the year. Since then, MRK stock has increased by 42.0% and is now trading at $108.84.
View the best growth stocks for 2022 here
.

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our MRK earnings forecast
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Thursday, October, 27th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.18. The company earned $14.96 billion during the quarter, compared to the consensus estimate of $14.05 billion. Merck & Co., Inc. had a net margin of 25.88% and a trailing twelve-month return on equity of 46.57%. The business's revenue for the quarter was up 13.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.75 earnings per share.
Read the conference call transcript
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 26th. Investors of record on Thursday, September 15th will be given a dividend of $0.69 per share on Friday, October 7th. This represents a $2.76 annualized dividend and a dividend yield of 2.54%. The ex-dividend date is Wednesday, September 14th.
Read our dividend analysis for MRK
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.76 per share and currently has a dividend yield of 2.54%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 45.92%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 37.60% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of $7.32-$7.37 for the period, compared to the consensus estimate of $7.34. The company issued revenue guidance of $58.50 billion-$59.00 billion, compared to the consensus revenue estimate of $58.51 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.84%), BlackRock Inc. (8.46%), State Street Corp (4.63%), Bank of New York Mellon Corp (1.22%), Massachusetts Financial Services Co. MA (1.07%) and Price T Rowe Associates Inc. MD (0.60%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Johannes Jacobus Oosthuizen, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay, Steven Mizell and Wendell P Weeks.
View institutional ownership trends
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $108.84.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $275.95 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $6.01 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

The company employs 68,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 11/30/2022 by MarketBeat.com Staff